26 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
business decisions entered into by drug innovators as a way to address risk and that these settlements should, therefore, be immune from antitrust attack … ; and (e) that antitrust liability for large unjustified payments does not prevent litigating parties from settling their lawsuits, for example, by allowing
ARS
h1a30
28 Apr 23
Annual report to shareholders
7:03am
424B4
vh3k61b7 vw1i6rpfzx
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
gnuuswzf5psqd pb
19 May 21
Draft registration statement
12:00am
10-K
116kgl6ul8g2iq
11 Mar 21
Annual report
4:19pm
10-Q
esx ioj78yu4inum
12 Nov 20
Quarterly report
4:28pm